2017
Mecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction 2017, 113: 6-14. PMID: 28710873, PMCID: PMC5725262, DOI: 10.1111/add.13943.Peer-Reviewed Original ResearchConceptsHeavy drinking daysDrinking daysAlcohol use disorderUse disordersAlcohol consumptionAlcohol dependenceDouble-blind clinical trialNicotinic acetylcholine receptor antagonistWeeks of treatmentAcetylcholine receptor antagonistCurrent alcohol dependenceSignificant differencesTreatment-seeking smokersMecamylamine treatmentPlacebo groupMonth 3Primary outcomeSmoking statusNicotine withdrawalReceptor antagonistNovel pharmacotherapiesClinical trialsManagement therapyMecamylamineTreatment groups
2016
A Randomized Trial of Contingency Management for Smoking Cessation During Intensive Outpatient Alcohol Treatment
Cooney JL, Cooper S, Grant C, Sevarino K, Krishnan-Sarin S, Gutierrez IA, Cooney NL. A Randomized Trial of Contingency Management for Smoking Cessation During Intensive Outpatient Alcohol Treatment. Journal Of Substance Use And Addiction Treatment 2016, 72: 89-96. PMID: 27542442, DOI: 10.1016/j.jsat.2016.07.002.Peer-Reviewed Original ResearchConceptsEnd of treatmentNicotine replacement therapyOutpatient alcohol treatmentContingency managementReplacement therapyDependent smokersQuit ratesAbstinence outcomesAlcohol treatmentEfficacy of CMEvidence-based smoking cessation treatmentOutpatient alcohol treatment programOne monthAlcohol-dependent smokersInitial smoking abstinenceSmoking cessation treatmentDrug use outcomesAlcohol treatment programsCognitive behavioral therapyCognitive behavior therapyCessation treatmentRandomized trialsSmoking cessationSmoking abstinenceClinical trials
2015
Concurrent Alcohol and Tobacco Treatment: Effect on Daily Process Measures of Alcohol Relapse Risk
Cooney NL, Litt MD, Sevarino KA, Levy L, Kranitz LS, Sackler H, Cooney JL. Concurrent Alcohol and Tobacco Treatment: Effect on Daily Process Measures of Alcohol Relapse Risk. Journal Of Consulting And Clinical Psychology 2015, 83: 346-358. PMID: 25622198, PMCID: PMC4380705, DOI: 10.1037/a0038633.Peer-Reviewed Original ResearchConceptsSmoking cessation interventionSmoking treatmentCessation interventionsSmoking abstinenceProcess measuresAlcohol treatmentOutpatient alcohol treatment programAlcohol-dependent smokersDaily smoking abstinenceAlcohol relapse riskOutpatient alcohol treatmentLow alcohol consumptionAlcohol treatment programsDependent smokersRelapse riskAlcohol abstinenceWaiting listInteractive voice response systemSmoking outcomesAlcohol consumptionCSC participantsVoice response systemIVR assessmentsTreatment programDaily assessment
2009
Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum
Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg HR, Pilkey DT, Sevarino K, Oncken CA, Litt MD. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. Addiction 2009, 104: 1588-1596. PMID: 19549054, PMCID: PMC2753831, DOI: 10.1111/j.1360-0443.2009.02624.x.Peer-Reviewed Original ResearchConceptsActive nicotine patchNicotine patchPlacebo gumNicotine gumSmoking cessationDouble-blind placebo-controlled clinical trialAlcohol treatmentPlacebo-controlled clinical trialBetter smoking outcomesCombination nicotine patchTransdermal nicotine patchDouble-blind conditionsSubstance abuse clinicsMonthly booster sessionsCombination nicotine replacementNicotine replacementCessation treatmentTobacco smokersLarge trialsCombination therapyMore cigarettesMedication conditionActive gumClinical trialsBooster sessions
2005
Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients
Oliveto A, Poling J, Sevarino K, Gonsai K, McCance-Katz E, Stine S, Kosten T. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug And Alcohol Dependence 2005, 79: 157-165. PMID: 16002025, DOI: 10.1016/j.drugalcdep.2005.01.007.Peer-Reviewed Original ResearchConceptsHC groupOpioid useContingency management proceduresCocaine useEfficacy of DoseOverall opioid useOpioid withdrawal symptomsHigh-dose groupLow-dose groupLY groupDrug-free urineCocaine-dependent patientsCocaine-dependent participantsBaseline characteristicsMaintenance doseWithdrawal symptomsClinical trialsCocaine abstinenceOpioidsLAAMUrine samplesHY groupAbstinenceDoseUrine
2003
Tiagabine increases cocaine‐free urines in cocaine‐dependent methadone‐treated patients: results of a randomized pilot study
Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR. Tiagabine increases cocaine‐free urines in cocaine‐dependent methadone‐treated patients: results of a randomized pilot study. Addiction 2003, 98: 1625-1632. PMID: 14616189, DOI: 10.1046/j.1360-0443.2003.00544.x.Peer-Reviewed Original ResearchConceptsMethadone-treated patientsCocaine-free urinesUrine drug testsDouble-blind placebo-controlled trialCocaine useVeterans Affairs Connecticut Healthcare SystemPlacebo-controlled trialDrug testsRandomized pilot studyOpiate Withdrawal ScaleStructured Clinical InterviewSelf-reported cocaine useTreatment Research ProgramAddiction Severity IndexGABAergic medicationsActive medicationStudy entrySelf-reported useWithdrawal ScaleTreatment groupsTiagabineTreatment retentionAverage ageClinical InterviewWeek 9Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients
Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug And Alcohol Dependence 2003, 70: 315-325. PMID: 12757969, DOI: 10.1016/s0376-8716(03)00032-2.Peer-Reviewed Original ResearchConceptsCocaine-free urinesContingency managementCocaine useOpioid withdrawal symptomsUrine toxicology resultsDrug-free urineMethadone treatmentPoor prognosisWithdrawal symptomsMethadone maintenancePlasma levelsDependent patientsToxicology resultsTreatment groupsCell trialsCocaine abuseBuprenorphineDesipraminePatientsCocaine abusersOpiatesSymptom levelsUrineAdditive effectCocaineClonidine and yohimbine in opioid-dependent humans responding under a naloxone novel-response discrimination procedure
Oliveto A, Sevarino K, McCance-Katz E, Benios T, Poling J, Feingold A. Clonidine and yohimbine in opioid-dependent humans responding under a naloxone novel-response discrimination procedure. Behavioural Pharmacology 2003, 14: 97-109. PMID: 12658070, DOI: 10.1097/00008877-200303000-00001.Peer-Reviewed Original ResearchConceptsAlpha2-adrenergic antagonist yohimbineNovel-response drug discrimination procedureAlpha2-adrenergic agonist clonidineOpioid-dependent humansPlacebo-appropriate respondingOpioid antagonist naloxoneClonidine-induced changesDose-related increaseEffects of yohimbineDoses of naloxoneDrug discrimination procedureOpioid withdrawalAdrenergic mechanismsAntagonist yohimbineAgonist clonidineAntagonist naloxoneOpioid antagonistClonidineLow doseNaloxoneTraining doseYohimbineDrug conditionsDiscrimination procedureDose
2000
Comparison of intravenous cocaethylene and cocaine in humans
Hart C, Jatlow P, Sevarino K, McCance-Katz E. Comparison of intravenous cocaethylene and cocaine in humans. Psychopharmacology 2000, 149: 153-162. PMID: 10805610, DOI: 10.1007/s002139900363.Peer-Reviewed Original ResearchConceptsBlood pressureActive drug conditionsDouble-blind studyDiastolic blood pressureSystolic blood pressureTransesterification of cocaineCocaine-dependent participantsStudy drugMetabolite of cocaineHeart rateSlow clearanceDrug conditionsSeparate daysHuman volunteersSubjective effectsPharmacological propertiesEquivalent dosesCocainePlaceboSignificant increaseSimilar differencesCocaethyleneExperimental sessionsSubjective measuresPrevious studies
1996
Preprothyrotropin-releasing hormone mRNA in the rat central gray is strongly and persistently induced during morphine withdrawal
Gahn L, Sevarino K. Preprothyrotropin-releasing hormone mRNA in the rat central gray is strongly and persistently induced during morphine withdrawal. Neuropeptides 1996, 30: 207-212. PMID: 8819143, DOI: 10.1016/s0143-4179(96)90065-7.Peer-Reviewed Original ResearchConceptsThyrotropin-releasing hormoneVentrolateral central grayCentral grayOpiate withdrawalMorphine withdrawalAcute naltrexone treatmentPrecipitation of withdrawalHormone mRNAChronic morphineNaltrexone treatmentSystemic administrationOpiate dependencePhysical symptomsVivo evidenceWithdrawalMorphineSignificant increaseRatsSitu hybridizationMRNA
1995
Regulation of Cytochrome c Oxidase Subunit mRNA and Enzyme Activity in Rat Brain Reward Regions During Withdrawal from Chronic Cocaine
Walker J, Sevarino K. Regulation of Cytochrome c Oxidase Subunit mRNA and Enzyme Activity in Rat Brain Reward Regions During Withdrawal from Chronic Cocaine. Journal Of Neurochemistry 1995, 64: 497-502. PMID: 7830041, DOI: 10.1046/j.1471-4159.1995.64020497.x.Peer-Reviewed Original ResearchConceptsMedial prefrontal cortexNucleus accumbensBrain regionsChronic cocaine treatmentCO activityChronic treatmentCocaine treatmentBrain reward regionsChronic cocaineDrug rewardPrefrontal cortexSubunit mRNAsIndividual ratsReward regionsCocaineNorthern blot analysisBlot analysisTime-dependent patternUnique time-dependent patternEnzyme activityRatsScreening procedureTreatmentMRNAMetabolic activity
1993
Cocaine Regulation of Brain Preprothyrotropin‐Releasing Hormone mRNA
Sevarino K, Primus R. Cocaine Regulation of Brain Preprothyrotropin‐Releasing Hormone mRNA. Journal Of Neurochemistry 1993, 60: 1151-1154. PMID: 8436966, DOI: 10.1111/j.1471-4159.1993.tb03267.x.Peer-Reviewed Original ResearchConceptsThyrotropin-releasing hormoneCocaine treatmentNucleus accumbensCocaine actionSolution hybridization RNase protectionMRNA levelsRat brain regionsChronic cocaine treatmentAcute cocaine treatmentPreclinical evidenceExtrahypothalamic regionsCocaine withdrawalMin postinjectionH postinjectionPrepro-TRHBrain regionsCocaine regulationCocaine reinforcementAmygdalaThalamusTRH precursorHippocampusHormone mRNASignificant decreaseRNase protection
1991
A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function
Terwilliger R, Beitner-Johnson D, Sevarino K, Crain S, Nestler E. A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Research 1991, 548: 100-110. PMID: 1651140, DOI: 10.1016/0006-8993(91)91111-d.Peer-Reviewed Original ResearchConceptsCyclic AMP systemChronic morphineNucleus accumbensBrain regionsAdenylate cyclaseAMP systemDorsal root ganglion/spinal cordG proteinsRat locus coeruleusMorphine regulationChronic treatmentLocus coeruleusSpinal cordChronic actionsOpiate toleranceAbused substancesMorphineAMP-dependent protein kinase activityCyclic AMP-dependent protein kinase activityNeuronal functionKinase activityDecreased levelsDrug addictionCocaineThalamus
1990
Chronic Cocaine Treatment Decreases Levels of the G Protein Subunits Giα and Goα in Discrete Regions of Rat Brain
Nestler E, Terwilliger R, Walker J, Sevarino K, Duman R. Chronic Cocaine Treatment Decreases Levels of the G Protein Subunits Giα and Goα in Discrete Regions of Rat Brain. Journal Of Neurochemistry 1990, 55: 1079-1082. PMID: 2117048, DOI: 10.1111/j.1471-4159.1990.tb04602.x.Peer-Reviewed Original ResearchConceptsVentral tegmental areaChronic cocaineTegmental areaNucleus accumbensBrain regionsLocus coeruleusGi alphaPertussis toxin-mediated ADP-ribosylationRat brain regionsTreatment of ratsG proteinsG protein ADP-ribosylationADP-ribosylation levelsElectrophysiological actionsBeta immunoreactivityADP-ribosylationChronic actionsRat brainCocaine actionGs alphaDecrease levelsAlpha levelsAccumbensImmunoreactivityCocaine